Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial - Jonathan W. Goldman, Yuanbin Chen, Mustafa Özgüroğlu, Maximilian J. Hochmair, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Mikhail Dvorkin, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V. Conev - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, The Lancet Oncology, 1(22), p. 51-65, 2021

DOI: 10.1016/s1470-2045(20)30539-8

Links

Tools

Export citation

Search in Google Scholar

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Journal article published in 2020 by Jonathan W. Goldman, Yuanbin Chen, Mustafa Özgüroğlu, Maximilian J. Hochmair, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Mikhail Dvorkin, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V. Conev and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO